Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk Adapted Therapy for Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma
NCT00384553Phase 2Unknown
- Sponsor
- University of Magdeburg
- Start
- Jun 2004
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, dexamethasone, cytarabine, cisplatin, treosulfan and 1 more in non-Hodgkin lymphoma (NHL), sponsored by University of Magdeburg. Primary endpoint: Toxicity. Status: unknown.
02
Drugs
rituximabdexamethasonecytarabinecisplatintreosulfan
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00384553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00384553.